Greater Madrid Metropolitan Area
Paco Moreno is a senior consultant, with more than thirty years of experience in technology transfer, innovation, entrepreneurship and creation of technology-based startups. From October 2020 to April 2022 he was Deputy Chief Strategy Officer at Arquimea Group, a cross-sectoral international technology group that developes solutions and innovative products in highly-demanding activity sectors. Arquimea is committed to supporting research and scientific development that improve people’s lives. Arquimea bets on companies and projects that provide value to society, contributing to boosting high-impact solutions and products and to building our Vision. From January 2004 to April 2020 he was Director of the Science &Technology Transfer Area at Fundación Botín, Spain’s leading private foundation in terms of the scale of its investment and the far-reaching impact of its programmes. He managed global technology transfer projects and coordinated project management and strategic planning activities related to ongoing research projects and, prior to that, was founder and chairman of PlacementPharma, S.L., and Mundifarma Consulting S.L.. PlacementPharma is a private consulting firm providing strategic analysis and corporate development services, including R&D and Regulatory Affairs, to the pharmaceutical, biotechnology and healthcare industries, Mundifarma Consulting is a private consulting firm specialized in the evaluation of strategic pharmaceutical Markets, R&D projects, portfolios, and platform technologies. Before founding his own companies, Francisco has served as a Manager for Basic & Preclinical Research with Ares Serono Group, S.A., Spain, a medium multinational pharmaceutical company with focus in biotechnology, at which he was responsible for all aspects of research and development in respect of basic and preclinical research and external scientific affairs. Specialties: His professional experience extends over Research & Development, Competitive Intelligence, Knowledge Management, Strategic Business Analysis, International Business and International Patent licensing.
Grant Thornton is a global network of 68,000 people in member firms in 147 markets with a common goal to help you realise your ambitions. Which is why our network combines global scale and capability with local insights and understanding. So, whether you’re growing in one market or many, looking to operate more effectively, managing risk and regulation, or realising stakeholder value, our member firms have the assurance, tax and advisory capabilities you need with the quality you expect. At Grant Thornton, we offer a comprehensive range of advisory services to help you achieve your goals. We help you create, transform and protect value. From finding ways to finance growth to understanding how to manage risk and regulation; from identifying opportunities to optimise operations, to getting the best from talent, our global network provides the expert support you need to thrive in a fast changing world. Explore your strategic growth options, advise on and project manage the chosen solution. Deliver valuation support during transactions and disputes and expert advice in support of regulatory and administrative matters. Define strategic goals and formulate solutions that keep you ahead of disruptive change Help you sustain and finance growth, manage risk and talent, optimise operations and protect value. Improve financial processes and systems, reduce costs and transform your finance function Engage, specify and deliver scalable technology solutions Help you make better use of increasingly large amounts of data, using tools and analysis to transform decision-making processes. Implement effective and reliable governance and compliance procedures. Help you understand and manage risk and seek an appropriate balance between risk and opportunities. Assess cyber risk and help you manage it by improving culture, technologies and processes. Provide a rapid, practical response to get you operating securely again as fast as possible in the event of a security incident.
With forty years of experience, the performing arts company La Fura dels Baus promotes the Èpica Foundation with the aim of leaving a legacy to subsequent generations, thus creating a center for experimentation and learning. Èpica is a space of knowledge transfer where, as in La Fura’s shows, all disciplines dialogue and interact based on a common goal. The hybridization between art, science and technology, the sum of talent and collective creation are the bases of its methodology, to which a social part must be added. Exploiting the possibilities of El Manresà, the neighborhood where the Foundation is located, and working with individuals at risk of exclusion to give them new tools and skills, are a fundamental part of Èpica’s principles. The Foundation also relies on a Council of Sages, which ensures that the concepts and activities carried out by Èpica are aligned with the future of society. La Fura dels Baus’ founding members are Miquel Badosa, Pep Gatell, Jurgen Müller, Àlex Ollé, Carles Padrissa and Pera Tantiñá.
At Nowture we invest in and promote innovation in life sciences in a unique and comprehensive way. We work to make the best ideas grow, connecting them with a powerful ecosystem of media, experience and knowledge to turn them into real, efficient and successful projects. We are here to make ideas that will transform the way we live come true, promoting innovative projects by people and organizations. We get involved in each project, being an active part of your team and your day to day. Designing and implementing specific strategies that allow us to channel ingenuity, ideas and innovation, in businesses that change our world. We guide innovation in the life sciences, so that the best ideas allow us to draw together a better future. We help improve our lives, yours, mine and that of those to come.
Cultured Food Technology (CFT) is an innovation-focused start-up born to optimize the growth, characterization and differentiation of the muscle stem cells needed to generate a meat product at a laboratory scale, providing our industrial partners the initial step to generate a high-quality and sustainable product.
In Silico Discovery (ISD) was founded with the objective of developing a target-based computational approach for the efficient discovery of new potential actives with application in the cosmeceutical area. ISD achieves this through a solid technological partnership with Nostrum BioDiscovery (NBD), a highly specialized company providing custom-made services and cutting-edge in silico technologies to biopharmaceutical and biotechnology companies, CROs and academia to perform rational drug design and protein engineering.